今年,糖尿病医生和心血管医生共同关注的一个热点就是阿司匹林在糖尿病患者一级预防中的真正价值。美国糖尿病协会(ADA)临床事务部副主席Kirkman博士甚至作出这样的发言,“由于近来的一些研究提示预防性服用阿司匹林的益处并不是非常大,而且服用阿司匹林确实存在一些风险(消化道出血或出血性中风),2010年1月的ADA新指南将建议把阿司匹林主要用于风险更高的人群,而不再像过去那样建议用于中等或更高风险的人群。”而对这个话题的讨论都源自新公布的两项研究结果。下面让我们来了解一下这两项引发热议的研究以及一位美国专家的分析。 This year, one of the hot spots of common concern between diabetes doctors and cardiologists is the true value of aspirin in primary prevention of diabetes. Dr. Kirkman, vice president of clinical practice at the American Diabetes Association (ADA), even made such a statement, “since recent studies suggest that the benefits of aspirin prophylaxis are not significant and there are some risks of taking aspirin (gastrointestinal bleeding or Hemorrhagic stroke), the January 2010 ADA guidelines will recommend that aspirin be used primarily in people at higher risk than in the past for people at moderate or higher risk. ” Discussions are based on two newly published findings. Let us look at the two hot research and an analysis by a U.S. expert.